Porcine Reproductive and Respiratory Syndrome vaccine virus
The present invention relates to modified, live Porcine Reproductive and Respiratory Syndrome viruses. Viruses were genetically analyzed and selected based on phylogenetic grouping for modification by repeated passage in tissue culture. The modified, live viruses were assessed for the ability to provide protective immunity to heterologous viruses. The modified, live viruses are useful in vaccines, particularly in vaccines which can treat infection of swine by multiple heterologous viruses.
1. A modified, live Porcine Reproductive and Respiratory Syndrome (PRRS) virus strain, wherein the consensus complementary DNA sequence of said PRRS strain is at least 95% identical to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4.
2. The modified, live PRRS virus strain of claim 1 , wherein the consensus complementary DNA sequence of said PRRS strain is at least 98% identical to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2,SEQ ID NO: 3, and SEQ ID NO: 4.
3. The modified, live PRRS virus strain of claim 1 , wherein said PRRS strain is a DE 14-3073 strain designated PTA-125490; an ES 13-49 strain designated PTA-125489; an IT 14-32 strain designated PTA-125488, or a PL 14-02 strain designated PTA-125487.
4. The PRRS strain of claim 1 , wherein said PRRS virus strain is passaged at least 85 times in tissue culture cells.
5. A product comprising a modified, live Porcine Reproductive and Respiratory Syndrome (PRRS) virus strain of claim 1 in the manufacture of a medicament for treating PRRS.
6. An immunogenic composition comprising a modified, live PRRS virus strain having a consensus complementary DNA sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and a pharmaceutically-acceptable excipient, stabilizer, solubilizer, or diluent.
7. An immunogenic composition comprising a modified, live PRRS virus strain having a consensus complementary DNA sequence of claim 6 that is at least 95% identical to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and a pharmaceutically-acceptable excipient, stabilizer, solubilizer, or diluent.
8. An immunogenic composition comprising a modified, live PRRS virus strain having a consensus complementary DNA sequence of claim 6 that is at least 98% identical to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and a pharmaceutically-acceptable excipient, stabilizer, solubilizer, or diluent.
9. The immunogenic composition of claim 6 , wherein the modified, live PRRS virus strain is a DE 14-3073 strain designated PTA-125490; an ES 13-49 strain designated PTA-125489; an IT 14-32 strain designated PTA-125488, or a PL 14-02 strain designated PTA-125487.
10. The immunogenic composition of claim 6 , further comprising an adjuvant.
11. A vaccine comprising a modified, live PRRS virus strain, wherein said PRRS virus strain is a DE 14-3073 strain designated PTA-125490; an ES 13-49strain designated PTA-125489; an IT 14-32 strain designated PTA-125488, or a PL 14-02 strain designated PTA-125487.
12. A vaccine comprising a modified, live PRRS virus strain of claim 6 for the use in treatment or prevention of a symptom of Porcine Reproductive and Respiratory Syndrome in a porcine animal.
13. A method of treating and/or preventing a symptom of Porcine Reproductive and Respiratory Syndrome (PRRS) in a porcine animal, comprising administering to said porcine animal an immunogenic composition of claim 6 comprising a modified, live PRRS virus strain having a consensus complementary DNA sequence at least 98% identical to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4.
14. The method of claim 13 , wherein the symptom of PRRS is caused by a PRRS virus infection in a porcine animal.
15. A method of treating and/or preventing a symptom of Porcine Reproductive and Respiratory Syndrome (PRRS) in a porcine animal, comprising administering to said porcine animal a vaccine of claim 11 comprising a modified, live PRRS virus strain, wherein said PRRS virus strain is a DE 14-3073 strain designated PTA-125490; an ES 13-49 strain designated PTA-125489; an IT 14-32 strain designated PTA-125488, or a PL 14-02 strain designated PTA-125487.
16. The method of claim 15 , wherein the symptom of PRRS is caused by a PRRS virus infection in a porcine animal.
17. A product comprising an immunogenic composition of claim 6 comprising a modified, live PRRS virus strain having a consensus complementary DNA sequence at least 98% identical to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4 in the manufacture of a medicament for treating or preventing a symptom of Porcine Reproductive and Respiratory Syndrome (PRRS) in a porcine animal.
18. The product of claim 17 , wherein the symptom of PRRS is caused by a PRRS virus infection in a porcine animal.
19. A product comprising a vaccine of claim 11 comprising a modified, live PRRS virus strain, wherein said PRRS virus strain is a DE 14-3073 strain designated PTA-125490; an ES 13-49 strain designated PTA-125489; an IT 14-32 strain designated PTA-125488, or a PL 14-02 strain designated PTA-125487 for treating and/or preventing a symptom of Porcine Reproductive and Respiratory Syndrome (PRRS) in a porcine animal.
20. The product of claim 19 , wherein the symptom of PRRS is caused by a PRRS virus infection in a porcine animal.